Richard Schilsky, MD, explains how comprehensive genomic profiling is qualifying patients with cancer to participate in clinical trials that provide treatment options for them that they might not otherwise be able to access. Dr. Schilsky provides an overview of ASCO's TAPUR study and shares his perspective on a multi-omics approach for clinical trial design. Richard Schilsky, MD, is the retired Chief Medical Officer and executive vice president of the American Society of Clinical Oncology (ASCO). Learn about the clinical benefit of CGP: Rare fusion detection: https://youtu.be/pDN8InXWx3I NTRK fusion testing: https://youtu.be/0zeO1oz6tbE Homologous Recombination Deficiency (HRD) testing: https://youtu.be/54yI7Sxvnfc Liquid biopsy CGP: https://youtu.be/nO-HsxY1afo Subscribe to the Illumina video channel http://www.youtube.com/subscription_center?add_user=IlluminaInc A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond. View customer spotlight videos https://www.youtube.com/playlist?list=PLKRu7cmBQlajfheLzgbI4S7xBn7IDbt79 View Illumina webinars https://www.youtube.com/playlist?list=PLKRu7cmBQlahpXlnrrXlQw9itVJ8yHwUZ View Illumina support videos https://www.youtube.com/playlist?list=PLKRu7cmBQlajbm2KGsICWb-JOnusJfYvM Facebook: https://www.facebook.com/illuminainc LinkedIn: https://www.linkedin.com/company/illumina Instagram: https://www.instagram.com/illuminainc/ Twitter: https://twitter.com/illumina